With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Donation drive in São Paulo aims to support 250 young women’s health and environmental responsibility
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
Subscribe To Our Newsletter & Stay Updated
